- Home
- TGE vs ALMS Comparison
TGE vs ALMS Comparison
Compare TGE & ALMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGE
- ALMS
- Stock Information
- Founded
- TGE 2023
- ALMS 2021
- Country
- TGE France
- ALMS United States
- Employees
- TGE N/A
- ALMS N/A
- Industry
- TGE Newspapers/Magazines
- ALMS
- Sector
- TGE Consumer Discretionary
- ALMS
- Exchange
- TGE Nasdaq
- ALMS NYSE
- Market Cap
- TGE 436.6M
- ALMS 402.6M
- IPO Year
- TGE N/A
- ALMS 2024
- Fundamental
- Price
- TGE $6.50
- ALMS $3.52
- Analyst Decision
- TGE
- ALMS Strong Buy
- Analyst Count
- TGE 0
- ALMS 7
- Target Price
- TGE N/A
- ALMS $24.50
- AVG Volume (30 Days)
- TGE 243.6K
- ALMS 841.5K
- Earning Date
- TGE 01-01-0001
- ALMS 08-12-2025
- Dividend Yield
- TGE N/A
- ALMS N/A
- EPS Growth
- TGE N/A
- ALMS N/A
- EPS
- TGE 1.64
- ALMS N/A
- Revenue
- TGE $77,014,000.00
- ALMS $17,389,000.00
- Revenue This Year
- TGE N/A
- ALMS N/A
- Revenue Next Year
- TGE N/A
- ALMS N/A
- P/E Ratio
- TGE $3.84
- ALMS N/A
- Revenue Growth
- TGE 81.03
- ALMS N/A
- 52 Week Low
- TGE $5.60
- ALMS $2.76
- 52 Week High
- TGE $37.02
- ALMS $13.50
- Technical
- Relative Strength Index (RSI)
- TGE N/A
- ALMS N/A
- Support Level
- TGE N/A
- ALMS N/A
- Resistance Level
- TGE N/A
- ALMS N/A
- Average True Range (ATR)
- TGE 0.00
- ALMS 0.00
- MACD
- TGE 0.00
- ALMS 0.00
- Stochastic Oscillator
- TGE 0.00
- ALMS 0.00
About TGE The Generation Essentials Group Class A Ordinary Shares
The Generation Essentials Group is a media and entertainment company. Its publications L'Officiel and The Art Newspaper publish print editions in a total of nearly 28 countries and territories and digital contents. It operate in the movie production sector having produced various Asia-focused movies. It operate in three operating segments: media and entertainment segment, hotel operations, hospitality and VIP services segment and strategic investment segment. Key revenue is generated from strategic investment segment that is engage in proprietary investments and management of portfolio, including listed and unlisted equity shares investments and movie income right investments.
About ALMS ALUMIS INC
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Company pipeline includes: ESK-001, TYK2, A-OO5, IRF5.